Understanding Corporate VCs’ Investment Criteria
Corporate VCs often differ from traditional venture capitalists by prioritizing strategic value over purely financial returns. Michael Ryan, Vice President of Venture Capital & Business Development at Boston Scientific, emphasized the company’s active role in investing: “We’re one of the most active acquirers in the medtech industry, generally deploying somewhere north of $100 million a year into venture investments.” For more information visit here: https://tinyurl.com/5nbabbry